HIV among People Who Inject Drugs in the Middle East and North Africa: Systematic Review and Data Synthesis

English version České info

Background:
It is perceived that little is known about the epidemiology of HIV infection among people who inject drugs (PWID) in the Middle East and North Africa (MENA). The primary objective of this study was to assess the status of the HIV epidemic among PWID in MENA by describing HIV prevalence and incidence. Secondary objectives were to describe the risk behavior environment and the HIV epidemic potential among PWID, and to estimate the prevalence of injecting drug use in MENA.

Methods and Findings:
This was a systematic review following the PRISMA guidelines and covering 23 MENA countries. PubMed, Embase, regional and international databases, as well as country-level reports were searched up to December 16, 2013. Primary studies reporting (1) the prevalence/incidence of HIV, other sexually transmitted infections, or hepatitis C virus (HCV) among PWIDs; or (2) the prevalence of injecting or sexual risk behaviors, or HIV knowledge among PWID; or (3) the number/proportion of PWID in MENA countries, were eligible for inclusion. The quality, quantity, and geographic coverage of the data were assessed at country level. Risk of bias in predefined quality domains was described to assess the quality of available HIV prevalence measures. After multiple level screening, 192 eligible reports were included in the review. There were 197 HIV prevalence measures on a total of 58,241 PWID extracted from reports, and an additional 226 HIV prevalence measures extracted from the databases.

We estimated that there are 626,000 PWID in MENA (range: 335,000–1,635,000, prevalence of 0.24 per 100 adults). We found evidence of HIV epidemics among PWID in at least one-third of MENA countries, most of which are emerging concentrated epidemics and with HIV prevalence overall in the range of 10%–15%. Some of the epidemics have however already reached considerable levels including some of the highest HIV prevalence among PWID globally (87.1% in Tripoli, Libya). The relatively high prevalence of sharing needles/syringes (18%–28% in the last injection), the low levels of condom use (20%–54% ever condom use), the high levels of having sex with sex workers and of men having sex with men (15%–30% and 2%–10% in the last year, respectively), and of selling sex (5%–29% in the last year), indicate a high injecting and sexual risk environment. The prevalence of HCV (31%–64%) and of sexually transmitted infections suggest high levels of risk behavior indicative of the potential for more and larger HIV epidemics.

Conclusions:
Our study identified a large volume of HIV-related biological and behavioral data among PWID in the MENA region. The coverage and quality of the data varied between countries. There is robust evidence for HIV epidemics among PWID in multiple countries, most of which have emerged within the last decade and continue to grow. The lack of sufficient evidence in some MENA countries does not preclude the possibility of hidden epidemics among PWID in these settings. With the HIV epidemic among PWID in overall a relatively early phase, there is a window of opportunity for prevention that should not be missed through the provision of comprehensive programs, including scale-up of harm reduction services and expansion of surveillance systems.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: HIV among People Who Inject Drugs in the Middle East and North Africa: Systematic Review and Data Synthesis. PLoS Med 11(6): e32767. doi:10.1371/journal.pmed.1001663
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001663

Souhrn

Zdroje

1. ObermeyerCM (2006) HIV in the Middle East. BMJ 333: 851–854.

2. UNAIDS (2010) Global Report: UNAIDS report on the global AIDS epidemic. Available: http://www.unaids.org/documents/20101123_GlobalReport_em.pdf. Accessed 16 May 2014.

3. AceijasC, StimsonGV, HickmanM, RhodesT (2004) Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18: 2295–2303.

4. AceijasC, FriedmanSR, CooperHL, WiessingL, StimsonGV, et al. (2006) Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect 82(Suppl 3): iii10–iii17.

5. LopezAD, MathersCD, EzzatiM, JamisonDT, MurrayCJ (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747–1757.

6. van GriensvenF, de Lind van WijngaardenJW, BaralS, GrulichA (2009) The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS 4: 300–307.

7. KilmarxPH (2009) Global epidemiology of HIV. Curr Opin HIV AIDS 4: 240–246.

8. AlkaiyatA, WeissMG (2013) HIV in the Middle East and North Africa: priority, culture, and control. Int J Public Health 58: 927–937.

9. BohannonJ (2005) Science in Libya. From pariah to science powerhouse? Science 308: 182–184.

10. SabaHF, KouyoumjianSP, MumtazGR, Abu-RaddadLJ (2013) Characterising the progress in HIV/AIDS research in the Middle East and North Africa. Sex Transm Infect 89(Suppl 3): iii5–iii9.

11. Abu-Raddad L, Akala FA, Semini I, Riedner G, Wilson D, et al.. (2010) Characterizing the HIV/AIDS epidemic in the Middle East and North Africa: time for Strategic Action. Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project. World Bank/UNAIDS/WHO Publication. Available: http://www-wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/2010/06/04/000333038_20100604011533/Rendered/PDF/548890PUB0EPI11C10Dislosed061312010.pdf. Accessed 16 May 2014. Washington (D.C.): The World Bank Press.

12. Abu-RaddadLJ, HilmiN, MumtazG, BenkiraneM, AkalaFA, et al. (2010) Epidemiology of HIV infection in the Middle East and North Africa. AIDS 24(Suppl 2): S5–23.

13. MumtazG, HilmiN, AkalaFA, SeminiI, RiednerG, et al. (2011) HIV-1 molecular epidemiology evidence and transmission patterns in the Middle East and North Africa. Sex Transm Infect 87: 101–106.

14. MumtazG, HilmiN, McFarlandW, KaplanRL, AkalaFA, et al. (2011) Are HIV epidemics among men who have sex with men emerging in the Middle East and North Africa?: a systematic review and data synthesis. PLoS Med 8: e1000444.

15. MumtazGR, RiednerG, Abu-RaddadLJ (2014) The emerging face of the HIV epidemic in the Middle East and North Africa. Curr Opin HIV AIDS 9: 183–191.

16. UNODC (2011) United Nations Office on Drugs and Crime (2011). World Drug Report. Available: http://www.unodc.org/documents/data-and-analysis/WDR2011/World_Drug_Report_2011_ebook.pdf. Accessed 16 May 2014.

17. BeyrerC, WirtzAL, BaralS, PeryskinaA, SifakisF (2010) Epidemiologic links between drug use and HIV epidemics: an international perspective. J Acquir Immune Defic Syndr 55(Suppl 1): S10–S16.

18. MoherD, LiberatiA, TetzlaffJ, AltmanDG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.

19. LiberatiA, AltmanDG, TetzlaffJ, MulrowC, GotzschePC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.

20. The Cochrane collaboration (2008) Cochrane handbook for systematic reviews of interventions. Higgins JPT, Green S, editors. Hoboken (New Jersey): Wiley-Blackweill.

21. World Health Organization African Index Medicus (AIM). Available: http://indexmedicus.afro.who.int/. Accessed 16 May 2014.

22. World Health Organization Index Medicus for the Eastern Mediterranean Region (IMEMR). Available: http://www.emro.who.int/lin/imemr.htm. Accessed 16 May 2014.

23. International AIDS Society International AIDS Conference Abstracts. Available: http://www.iasociety.org/Default.aspx?pageId=7. Accessed 16 May 2014.

24. International AIDS Society IAS Conference on HIV Pathogenesis and Treatment Abstracts. Available: http://www.iasociety.org/Default.aspx?pageId=7. Accessed 16 May 2014.

25. International Society for Sexually Transmitted Diseases Research (ISSTDR) ISSTDR Conference Abstracts. Available: http://www.isstdr.org/previous-meetings.php. Accessed 16 May 2014.

26. U.S Department of Commerce United States Census Bureau International Database, Washington (D.C.). Available: http://www.census.gov/population/international/data/hiv/interactive/. Accessed 16 May 2014.

27. WHO/EMRO Regional database on HIV testing. Cairo: WHO Regional Office for the Eastern Mediterranean.

28. UNAIDS (2008) UNAIDS/WHO/UNICEF Epidemiological Fact Sheets database on HIV and AIDS. Geneva: UNAIDS.

29. VickermanP, MartinNK, HickmanM (2012) Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings–implications for intervention impact. Drug Alcohol Depend 123: 122–131.

30. VickermanP, HickmanM, MayM, KretzschmarM, WiessingL (2010) Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction 105: 311–318.

31. MathersBM, DegenhardtL, PhillipsB, WiessingL, HickmanM, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733–1745.

32. IDU Reference Group, The reference group to the UN on HIV and Injecting Drug Use. Available: https://ndarc.med.unsw.edu.au/project/injecting-drug-users-reference-group-reference-group-un-hiv-and-injecting-drug-use. Accessed 16 May 2014.

33. United Nations Population Division. World Population Prospects: the 2010 Revision Population Database. Available: http://esa.un.org/unpd/wpp/index.htm. Accessed 16 May 2014.

34. UNAIDS/WHO working group on global HIV/AIDS and STI surveillance (2011) Guidelines on surveillance among populations most at risk for HIV. Geneva: WHO Press. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2011/20110518_Surveillance_among_most_at_risk.pdf. Accessed 16 May 2014.

35. WilsonD, HalperinDT (2008) “Know your epidemic, know your response”: a useful approach, if we get it right. Lancet 372: 423–426.

36. UNAIDS/WHO working group on global HIV/AIDS and STI surveillance (2011) Guidelines for second generation HIV surveillance: an update: know your epidemic. Geneva: WHO Press. Available: http://apps.who.int/iris/bitstream/10665/85511/1/9789241505826_eng.pdf. Accessed 16 May 2014.

37. Pakistan National AIDS Control Program (2011) HIV second generation surveillance In Pakistan. National report round IV. Canada-Pakistan HIV/AIDS Surveillance Project. National Aids Control Program, Ministry Of Health, Pakistan. Available: http://www.nacp.gov.pk/library/reports/Surveillance%20&%20Research/HIV-AIDS%20Surveillance%20Project-HASP/HIV%20Second%20Generation%20Surveillance%20in%20Pakistan%20-%20National%20report%20Round%20IV%202011.pdf. Accessed 16 May 2014.

38. Afghanistan National AIDS Control Program (2010) Integrated Behavioral & Biological Surveillance (IBBS) in Afghanistan: year 1 report. HIV Surveillance Project - Johns Hopkins University School of Public Health, National AIDS Control Program, Ministry of Public Health. Kabul, Afghanistan.

39. Afghanistan National AIDS Control Program (2012) Integrated Behavioral & Biological Surveillance (IBBS) in selected cities of Afghanistan: findings of 2012 IBBS survey and comparison to 2009 IBBS survey. Johns Hopkins University School of Public Health, National AIDS Control Program, Ministry of Public Health. Kabul, Afghanistan.

40. Family Health International and Ministry of Health Egypt (2006) HIV/AIDS Biological & Behavioral Surveillance Survey: round one summary report, Cairo, Egypt 2006. FHI in collaboration with the Ministry of Health and support from USAID – IMPACT project. Available: http://www.fhi360.org/sites/default/files/media/documents/EgyptBioBSSsummaryreport2006.pdf. Accessed 16 May 2014.

41. SolimanC, RahmanIA, ShawkyS, BahaaT, ElkamhawiS, et al. (2010) HIV prevalence and risk behaviors of male injection drug users in Cairo, Egypt. AIDS 24(Suppl 2): S33–38.

42. Family Health International and Ministry of Health Egypt (2010) HIV/AIDS Biological & Behavioral Surveillance Survey: Round Two Summary Report, Cairo, Egypt 2010. FHI in collaboration with the Ministry of Health and support from the Global Fund. Available: http://www.fhi360.org/sites/default/files/media/documents/BBSS%202010_0.pdf. Accessed 16 May 2014.

43. Iran Ministry of Health and Medical Education, Kyoto University School of Public Health (Japan) (2008) Integrated bio-behavioral surveillance for HIV infection among injecting drug users in Iran. Draft of the 1st analysis on the collected data. Tehran: Iran Ministry of Health and Medical Education.

44. Iran Ministry of Public Health (2010) HIV bio-behavioral surveillance survey among injecting drug users in the Islamic Repubic of Iran. Final report [Persian], Tehran: Iran Ministry of Public Health.

45. Jordan National AIDS Program (2010) Preliminary analysis of Jordan IBBSS among injecting drug users. Amman: Ministry of Health.

46. MahfoudZ, AfifiR, RamiaS, El KhouryD, KassakK, et al. (2010) HIV/AIDS among female sex workers, injecting drug users and men who have sex with men in Lebanon: results of the first biobehavioral surveys. AIDS 24(Suppl 2): S45–S54.

47. MirzoyanL, BerendesS, JefferyC, ThomsonJ, Ben OthmanH, et al. (2013) New evidence on the HIV epidemic in Libya: why countries must implement prevention programs among people who inject drugs. J Acquir Immune Defic Syndr 62: 577–583.

48. Kingdom of Morocco Ministry of Public Health (2012) Country Report on UNGASS Declaration of Commitment. Rabat: Kingdom of Morocco Ministry of Public Health

49. Palestine Ministry of Health (2011) HIV bio-behavioral survey among injecting drug users in the East Jerusalem Governorate, 2010. Ramallah: Palestine Ministry of Health.

50. Pakistan National AIDS Control Program (2008) HIV second generation surveillance in Pakistan. National Report Round III. Canada-Pakistan HIV/AIDS Surveillance Project. National Aids Control Program, Ministry Of Health, Pakistan. Available: http://www.nacp.gov.pk/library/reports/Surveillance%20&%20Research/HIV-AIDS%20Surveillance%20Project-HASP/HIV%20Second%20Generation%20Surveillance%20in%20Pakistan%20-%20National%20report%20Round%20III%202008.pdf. Accessed 16 May 2014.

51. Pakistan National AIDS Control Program (2006–07) HIV second generation surveillance in Pakistan. National Report Round II. Canada-Pakistan HIV/AIDS Surveillance Project. National Aids Control Program, Ministry Of Health, Pakistan. Available: http://www.nacp.gov.pk/library/reports/Surveillance%20&%20Research/HIV-AIDS%20Surveillance%20Project-HASP/HIV%20Second%20Generation%20Surveillance%20in%20Pakistan%20-%20Round%202%20Report%202006-07.pdf. Last accessed 16 May 2014.

52. Pakistan National AIDS Control Program (2005) HIV second generation surveillance in Pakistan. National Report Round I. Canada-Pakistan HIV/AIDS Surveillance Project. National Aids Control Program, Ministry Of Health, Pakistan. Available: http://www.nacp.gov.pk/library/reports/Surveillance%20&%20Research/HIV-AIDS%20Surveillance%20Project-HASP/HIV%20Second%20Generation%20Surveillance%20in%20Pakistan%20-%20Round%201%20Report%20-%202005.pdf. Accessed 16 May 2014.

53. Tunisia Ministry of Health, Tunisian Association for Information and Orientation on HIV (2013) Enquête sérocomportementale du VIH et des hépatites virales C auprès des usagers de drogues injectables en Tunisie [French]. Biobehavioral surveillance of HIV and Hepatitis C among injecting drug users in Tunisia. Tunis: Tunisia Ministry of Health, Tunisian Association for Information and Orientation on HIV.

54. Tunisia Ministry of Health (2010) Synthèse des enquêtes de séroprévalence et sérocomportementales auprès de trois populations à vulnérables au VIH: Les usagers de drogues injectables, les hommes ayant des rapports sexuels avec des hommes et les travailleuses du sexe clandestines en Tunisie [French]. Synthesis of biobehavioral surveillance among the three populations vulnerable to HIV in Tunisia: Injecting drug users, men who have sex with men, and female sex workers. Tunis: Tunisia Ministry of Health.

55. MeysamieA, SedaghatM, MahmoodiM, GhodsiSM, EftekharB (2009) Opium use in a rural area of the Islamic Republic of Iran. Eastern Mediterranean Health Journal 15: 425–431.

56. MeratS, RezvanH, NouraieM, JafariE, AbolghasemiH, et al. (2010) Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 14(Suppl 3): e113–116.

57. EmmanuelF, BlanchardJ, ZaheerHA, RezaT, Holte-McKenzieM, et al. (2010) The HIV/AIDS Surveillance Project mapping approach: an innovative approach for mapping and size estimation for groups at a higher risk of HIV in Pakistan. AIDS 24(Suppl 2): S77–84.

58. Oman Ministry of Health (2006) HIV risk among heroin and injecting drug users in Muscat, Oman. Quantitative survey. Preliminary data. Muscat: Oman Ministry of Health.

59. Syria Mental Health Directorate, Syria National AIDS Programme (2008) Assessment of HIV risk and sero-prevalence among drug users in greater Damascus. Damascus: Syrian Ministry of Health. UNODC. UNAIDS.

60. Al-HaddadMK, KhashabaAS, BaigBZ, KhalfanS (1994) HIV antibodies among intravenous drug users in Bahrain. J Commun Dis 26: 127–132.

61. Morocco Ministry of Health (February 2010) Situation épidémiologique du VIH/Sida et des IST au Maroc [French]. Epidemiological assessment of HIV/AIDS and STIs in Morocco. Rabat Morocco Ministry of Health.

62. MojtahedzadehV, RazaniN, MalekinejadM, VazirianM, ShoaeeS, et al. (2008) Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system. AIDS Behav 12: S7–S12.

63. Todd C, Nasir A, Stanekzai MR, Rasuli MZ, Fiekert, et al.. (2010) Hepatitis C and HIV incidence among injecting drug users in Kabul, Afghanistan [Abstract MOPDC101]. In: Proceedings of AIDS 2010 - XVIII International AIDS Conference; 18–23 July 2010; Vienna, Austria.

64. Hadi DHMH, Shujaat PDMGSH, Waheed PDWuZ, Masood PDMGMA (2005) Incidence of hepatitis C virus and HIV among injecting drug users in Northern Pakistan: a prospective cohort study [Abstract MoOa0104]. In Proceedings: IAS 2005 - The 3rd IAS Conference on HIV Pathogenesis and Treatment; 24–27 July 2005; Rio de Janeiro, Brazil.

65. JahaniMR, KheirandishP, HosseiniM, ShirzadH, SeyedalinaghiSA, et al. (2009) HIV seroconversion among injection drug users in detention, Tehran, Iran. AIDS 23: 538–540.

66. Nai Zindagi, Punjab Provincial AIDS Control Program (2009) Rapid situation assessments of HIV prevalence and risk factors among people injecting drugs in four cities of the Punjab. Punjab: Nai Zindagi, Punjab Provincial AIDS Control Program

67. KazerooniPA, LariMA, JoolaeiH, ParsaN (2010) Knowledge and attitude of male intravenous drug users on HIV/AIDS associated high risk behaviors in Shiraz Pir-Banon jail, Fars Province, Southern Iran. Iranian Red Crescent Medical Journal 12: 334–336.

68. AsadiS, MarjaniM (2006) Prevalence of intravenous drug use-associated infections. Iranian Journal of Clinical Infectious Diseases 1: 59–62.

69. ToddCS, NasirA, StanekzaiMR, FiekertK, RasuliMZ, et al. (2011) Prevalence and correlates of HIV, syphilis, and hepatitis B and C infection and harm reduction program use among male injecting drug users in Kabul, Afghanistan: A cross-sectional assessment. Harm Reduct J 8: 22.

70. KuoI, ul-HasanS, GalaiN, ThomasDL, ZafarT, et al. (2006) High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J 3: 26.

71. HaqueN, ZafarT, BrahmbhattH, ImamG, ul HassanS, et al. (2004) High-risk sexual behaviours among drug users in Pakistan: implications for prevention of STDs and HIV/AIDS. Int J STD AIDS 15: 601–607.

72. Nai Zindagi, UNODCCP, UNAIDS. (1999) Baseline study of the relationship between injecting drug use, HIV and Hepatitis C among male injecting drug users in Lahore. Lahore: Nai Zindagi, UNODCCP, UNAIDS

73. StrathdeeSA, ZafarT, BrahmbhattH, BakshA, ul HassanS (2003) Rise in needle sharing among injection drug users in Pakistan during the Afghanistan war. Drug Alcohol Depend 71: 17–24.

74. AltafA, ShahSA, ZaidiNA, MemonA, Nadeem urR, et al. (2007) High risk behaviors of injection drug users registered with harm reduction programme in Karachi, Pakistan. Harm Reduct J 4: 7.

75. Altaf A, Shah SA, Memon A (2003) Follow up study to assess and evaluate knowledge, attitude and high risk behaviors and prevalence of HIV, HBV, HCV and Syphilis among IDUS at Burns Road DIC, Karachi. External report submitted to UNODC. Karachi: Marie Adelaide Habilitation Programme.

76. ToddCS, NasirA, Raza StanekzaiM, AbedAM, StrathdeeSA, et al. (2010) Prevalence and correlates of syphilis and condom use among male injection drug users in four Afghan cities. Sex Transm Dis 37: 719–725.

77. Aaraj E Report on the situation analysis on vulnerable groups in Beirut, Lebanon. Beirut: Lebanon Ministry of Health.

78. Burns K (2007) Women injecting drug users in Morocco: a study of women's vulnerability to HIV. Unofficial translation from the original French. GTZ Morocco.

79. AlipourA, HaghdoostAA, SajadiL, ZolalaF (2013) HIV prevalence and related risk behaviours among female partners of male injecting drugs users in Iran: results of a bio-behavioural survey, 2010. Sex Transm Infect 89(Suppl 3): iii41–iii44.

80. Mishwar IBBS_Lebanon (2008) Mishwar. An integrated bio-behavioral surveillance study among four vulnerable groups in lebanon: men who have sex with men; prisoners; commercial sex workers and intravenous drug users. Mid-term Report. Beirut: Mishwar IBBS_Lebanon.

81. BaqiS, NabiN, HasanSN, KhanAJ, PashaO, et al. (1998) HIV antibody seroprevalence and associated risk factors in sex workers, drug users, and prisoners in Sindh, Pakistan. J Acquir Immune Defic Syndr Hum Retrovirol 18: 73–79.

82. ParvizS, FatmiZ, AltafA, McCormickJB, Fischer-HochS, et al. (2006) Background demographics and risk behaviors of injecting drug users in Karachi, Pakistan. Int J Infect Dis 10: 364–371.

83. BokhariA, NizamaniNM, JacksonDJ, RehanNE, RahmanM, et al. (2007) HIV risk in Karachi and Lahore, Pakistan: an emerging epidemic in injecting and commercial sex networks. Int J STD AIDS 18: 486–492.

84. RazzaghiEM, MovagharAR, GreenTC, KhoshnoodK (2006) Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J 3: 12.

85. EmmanuelF, FatimaM (2008) Coverage to curb the emerging HIV epidemic among injecting drug users in Pakistan: delivering prevention services where most needed. Int J Drug Policy 19(Suppl 1): S59–S64.

86. KhananiMR, SomaniM, RehmaniSS, VerasNM, SalemiM, et al. (2011) The spread of HIV in Pakistan: bridging of the epidemic between populations. PLoS ONE 6: e22449.

87. RamezaniA, MohrazM, GachkarL (2006) Epidemiologic situation of human immunodeficiency virus (HIV/AIDS patients) in a private clinic in Tehran, Iran. Arch Iran Med 9: 315–318.

88. Burrows D, Wodak A, WHO (2005) Harm reduction in Iran. Issues in national scale-up. Report for World Health Organization. Geneva: WHO.

89. Nai Zindagi, Punjab Provincial AIDS Control Program (2008) The hidden truth: a study of HIV vulnerability, risk factors and prevalence among men injecting drugs and their wives. Lahore: Government of Punjab.

90. Mumtaz G, Hilmi N, Zidouh A, El Rhilani H, Alami K, et al.. (2010) HIV modes of transmission analysis in Morocco. Rabat: Kingdom of Morocco Ministry of Health and National STI/AIDS Programme, Joint United Nations Programme on HIV/AIDS, and Weill Cornell Medical College - Qatar.

91. MumtazGR, KouyoumjianSP, HilmiN, ZidouhA, El RhilaniH, et al. (2013) The distribution of new HIV infections by mode of exposure in Morocco. Sex Transm Infect 89(Suppl 3): iii49–iii56.

92. GouwsE, CuchiP (2012) on behalf of the International Collaboration on Estimating HIV Incidence by Modes of Transmission (inlcluding Laith J. Abu-Raddad and Ghina R. Mumtaz) (2012) Focusing the HIV response through estimating the major modes of HIV transmission: a multi-country analysis. Sex Transm Infect 88: i76–i85.

93. RutherfordGW, McFarlandW, SpindlerH, WhiteK, PatelSV, et al. (2010) Public health triangulation: approach and application to synthesizing data to understand national and local HIV epidemics. BMC Public Health 10: 447.

94. Tawilah J, Ball A (2003) WHO/EMRO & WHO/HQ Mission to Libyan Arab Jamahiriya to Undertake an Initial Assessment of the HIV/AIDS and STI Situation and National AIDS Programme. Tripoli. 15–19 June 2003.

95. HasnainM (2005) Cultural approach to HIV/AIDS harm reduction in Muslim countries. Harm Reduct J 2: 23.

96. Harm Reduction International (2012) The global state of harm reduction 2012: towards an integrated response. Available: http://www.ihra.net/files/2012/07/24/GlobalState2012_Web.pdf. Accessed 16 May 2014.

97. Asfhar P, Kasrace F (2005) HIV prevention experiences and programs in Iranian Prisons [MoPC0057]. In: Proceedings Seventh International Congress on AIDS in Asia and the Pacific; 1–5 July 2005; Kobe, Japan.

98. WHO Regional Office for the Eastern Mediterranean (2004) Best practice in HIV/AIDS prevention and care for injecting drug abusers: the triangular clinic in Kermanshah, Islamic Republic of Iran. Cairo: WHO Regional Office for the Eastern Mediterranean.

99. RazaniN, MohrazM, KheirandishP, MalekinejadM, MalekafzaliH, et al. (2007) HIV risk behavior among injection drug users in Tehran, Iran. Addiction 102: 1472–1482.

100. Nassirimanesh B, Trace M, Roberts M (2005) The rise of harm reduction in the Islamic Republic of Iran. Briefing Paper Eight, for the Beckley Foundation, Drug Policy Program. Oxford: The Beckley Foundation.

101. Iran Ministry of Health (2006) Treatment and medical education. Islamic Republic of Iran HIV/AIDS situation and response analysis. Tehran: Iran Ministry of Health.

102. ZamaniS, KiharaM, GouyaMM, VazirianM, NassirimaneshB, et al. (2006) High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran, Iran. J Acquir Immune Defic Syndr 42: 342–346.

103. UNAIDS/WHO (2004) AIDS epidemic update 2004. Geneva: UNAIDS/WHO.

104. ToddCS, NassiramaneshB, StanekzaiMR, KamarulzamanA (2007) Emerging HIV epidemics in Muslim countries: assessment of different cultural responses to harm reduction and implications for HIV control. Curr HIV/AIDS Rep 4: 151–157.

105. ZamaniS, FarniaM, TavakoliS, GholizadehM, NazariM, et al. (2010) A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran. Int J Drug Policy 21: 167–172.

106. VazirianM, NassirimaneshB, ZamaniS, Ono-KiharaM, KiharaM, et al. (2005) Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: a cross-sectional study. Harm Reduct J 2: 19.

107. ZamaniS, VazirianM, NassirimaneshB, RazzaghiEM, Ono-KiharaM, et al. (2010) Needle and syringe sharing practices among injecting drug users in Tehran: a comparison of two neighborhoods, one with and one without a needle and syringe program. AIDS Behav 14: 885–890.

108. Bolhari J, Alvandi M, Afshar P, Bayanzadeh A, Rezaii M, et al.. (2002) Assessment of drug abuse in Iranian Prisons. New York: United National Drug Control Programme (UNDCP).

109. Abu-Raddad L, Akala FA, Semini I, Riedner G, Wilson D, et al.. (2010) Policy notes. Characterizing the HIV/AIDS epidemic in the Middle East and North Africa: time for strategic action. Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project. World Bank/UNAIDS/WHO Publication. Washington (D.C.): The World Bank Press.

110. WHO/EMRO (2007) Progress towards Universal Access to HIV prevention, treatment and care in the health sector: report on an indicator survey for the year 2007 in the WHO Eastern Mediterranean Region. Geneva: WHO/EMRO.

111. WHO/EMRO (2008) Progress towards Universal Access to HIV Prevention, treatment and care in the health sector; report on an indicator survey for the year 2007 in the WHO Eastern Mediterranean Region. Geneva: WHO/EMRO.

112. BenjaberK, ReyJL, HimmichH (2005) A study on antiretroviral treatment compliance in Casablanca (Morocco) [French]. Med Mal Infect 35: 390–395.

113. Al DhahrySH, ScrimgeourEM, Al SuwaidAR, Al LawatiMR, El KhatimHS, et al. (2004) Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations. AIDS Res Hum Retroviruses 20: 1166–1172.

114. UNAIDS RST MENA(2008) Notes on AIDS in the Middle East and North Africa. Cairo: UNAIDS RST MENA.

115. RazzaghiE, NassirimaneshB, AfsharP, OhiriK, ClaesonM, et al. (2006) HIV/AIDS harm reduction in Iran. Lancet 368: 434–435.

116. Middle East and North Africa Harm Reduction Association (MENAHRA). Available: http://www.menahra.org/. Accessed 16 May 2014.

117. Morocco Ministry of Health, National Aids Control Program, National Institute of Hygiene, UNAIDS, Global Fund to Fight AIDS Tuberculosis and Malaria (2012) HIV integrated behavioral and biological surveillance surveys-Morocco 2011–2012: injecting drug users in Tanger and Nador, Morocco. Rabat, Morocco. Rabat: Morocco Ministry of Health, National Aids Control Program, National Institute of Hygiene, UNAIDS, Global Fund to Fight AIDS Tuberculosis and Malaria.

118. CollumbienM, ChowJ, QureshiAA, RabbaniA, HawkesS (2008) Multiple risks among male and transgender sex workers in Pakistan. J LGBT Health Res 4: 71–79.

119. Des JarlaisDC, MarmorM, PaoneD, TitusS, ShiQ, et al. (1996) HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 348: 987–991.

120. MetzgerDS, WoodyGE, McLellanAT, O'BrienCP, DruleyP, et al. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6: 1049–1056.

121. van AmeijdenEJ, WattersJK, van den HoekJA, CoutinhoRA (1995) Interventions among injecting drug users: do they work? Aids 9(Suppl A): S75–S84.

122. WHO/UNAIDS/UNICEF (2008) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2008. Geneva: WHO/UNAIDS/UNICEF.

123. Jenkins C, Robalino DA (2003) HIV in the Middle East and North Africa: the cost of inaction. Orientations in Development Series: Washington (D.C.): World Bank.

124. Afghanistan Ministry of Public Health, Director General of Preventive Medicine and Primary Health Care, Communicable Disease Directorate (CDC) (2012) Islamic Republic of Afghanistan. Country report on UNGASS Declaration of Commitment. Kabul: Afghanistan Ministry of Public Health, Director General of Preventive Medicine and Primary Health Care, Communicable Disease Directorate (CDC).

125. UNODC (2010) Afghanistan drug use survey 2009: executive summary. Kabul: UNODC Afghanistan Office.

126. World Health Organization - Eastern Mediterranean Region (2013) HIV surveillance systems: regional update 2012. Cairo: WHO Eastern Mediterranean Region.

127. NasirA, ToddCS, StanekzaiMR, BautistaCT, BotrosBA, et al. (2011) Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities. Int J Drug Policy 22: 145–152.

128. ToddCS, AbedAMS, StrathdeeSA, ScottPT, BotrosBA, et al. (2007) HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerging Infectious Diseases 13: 1327–1331.

129. Elghamrawy E, Abaza O, Abou Elmagd S, Ramy H, Atallah S, et al.. Risk behaviours among male injecting drug users in Egypt [Abstract MOPE227 2012]. In Proceedings AIDS 2012 - XIX International AIDS Conference; July 22–27; Washington (D.C.), United States of America.

130. Saleh E, El-Ghazzawi E, El-Sherbini I, Drew W, McFarland W, et al.. (1998) Sentinel surveillance for HIV and high risk behaviors among injection drug users in Alexandria, Egypt [Abstract 13124]. In: Proceedings AIDS 1998 - XII International AIDS Conference; 28 June–3 July 1998; Geneva, Switzerland.

131. Attia, MedhatS (1996) HIV seropositivity and KAP towards AIDS among drug addicts in Alexandria. Bull High Inst Public Health 26: 1–8.

132. Hasan M, Farag A, Ismail M (1994) AIDS and intravenous drug users in Egypt [Abstract PC0143]. In: Proceedings AIDS 1994 - X International AIDS Conference; 1994; Yokohama, Japan.

133. El-GhazzawiE, HunsmannG, SchneiderJ (1987) Low prevalence of antibodies to HIV-1 and HTLV-I in Alexandria, Egypt. AIDS Forsch 2: 639.

134. HonarvarB, OdoomiN, MoghadamiM, Afsar KazerooniP, HassanabadiA, et al. (2013) Blood-borne hepatitis in opiate users in iran: a poor outlook and urgent need to change nationwide screening policy. PLoS ONE 8: e82230.

135. MehrjerdiZA, AbarashiZ, NorooziA, ArshadL, ZarghamiM (2013) Correlates of shared methamphetamine injection among methamphetamine-injecting treatment seekers: the first report from Iran. Int J STD AIDS

136. IlamiO, SarkariB, KhosravaniA, Akbartabar ToriM, HosseiniZ (2012) HIV Seroprevalence among high-risk groups in Kohgiloyeh and Boyerahmad Province, southwest of Iran, a behavioral surveillance survey. AIDS Behav 16: 86–90.

137. HashemipourM, NokhodianZ, YaranM, AtaeiB, TayeriK, et al. (2013) Prevalence of HIV infection in individuals with history of intravenous drug use via community announcement in Isfahan-Iran. Pakistan Journal of Medical Sciences 29: 395–398.

138. DibajR, AtaeiB, YaranM, NokhodianZ, TayeriK, et al. (2013) Prevalence of HIV infection in inmates with history of injection drug use and evaluation of risk factors, in Isfahan, Iran. Pakistan Journal of Medical Sciences 29: 399–402.

139. JavadiA, AtaeiB, YaranM, NokhodianZ, KassaianN, et al. (2013) Prevalence of HIV infection and related risk factors in Isfahan Drop in Centers. Pakistan Journal of Medical Sciences 29: 346–350.

140. EskandariehS, NikfarjamA, TarjomanT, NasehiA, JafariF, et al. (2013) Descriptive aspects of injection drug users in Iran's national harm reduction program by methadone maintenance treatment. Iran J Public Health 42: 588–593.

141. ZamaniS, RadfarR, NematollahiP, FadaieR, MeshkatiM, et al. (2010) Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peer-driven sampling in Iran. Int J Drug Policy 21: 493–500.

142. GhasemianR, NajafiN, AmirkhanlooK (2011) The study of infections due to injection drug abuse in the injecting drug users hospitalized at Imam Khomeini Hospital in Sari and Razi Hospital in Ghaemshahr in 2007–2009. Journal of Mazandaran University of Medical Sciences 21: 8–15.

143. ZadehAOT, SeyedAlinaghiS, HassanzadFF, HajizadehM, MohamadiS, et al. (2014) Prevalence of HIV infection and the correlates among homeless in Tehran, Iran. Asian Pacific Journal of Tropical Biomedicine 4: 65–68.

144. AlinaghiSAS, ZadehAOT, ZaresefatH, HajizadehM, MohamadiSN, et al. (2013) Prevalence of HIV infection and the correlates among beggars in Tehran, Iran. Asian Pacific Journal of Tropical Disease 3: 76–78.

145. AminzadehZ (2007) Seroepidemiology of HIV, syphilis, hepatitis B and C in intravenous drug users at Loghman Hakim hospital]. Iran J Med Meicrobiol 1: 53–56.

146. Rahimi-MovagharA, RazaghiEM, Sahimi-IzadianE, Amin-EsmaeiliM (2010) HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis 14: e28–33.

147. KheirandishP, SeyedalinaghiSA, HosseiniM, JahaniMR, ShirzadH, et al. (2010) Prevalence and correlates of HIV infection among male injection drug users in detention in Tehran, Iran. J Acquir Immune Defic Syndr 53: 273–275.

148. Malekinejad M, Mohraz M, Razani N, Khairandish P, McFarland W, et al.. (2008) HIV and related risk behaviors of injecting drug users (IDU) in Iran: findings from the first respondent-driven sampling (RDS) survey of IDU in Tehran in 2006–2007 [Abstract THAC0202] 2008; Mexico.

149. AlaviSM, NadimiM, ShokriS, ZamaniG (2012) Seroepidemiology of human immunodeficiency virus in Illicit substance users in Ahvaz, Iran: 2005–2006. Jundishapur Journal of Microbiology 5: 474–478.

150. GhanbarzadehN, Nadjafi SemnaniM (2006) A study of HIV and other sexually transmitted infections among female prisoners in Birjand [Persian]. Journal of Birjand University of Medical Sciences 13: 69–75.

151. TofigiH, GhorbaniM, AkhlaghiM, YaghmaeiA, MostafazadehB, et al. (2011) Incidence of hepatitis B and HIV virus at cadaver of IV drug abusers in Tehran. Acta Med Iran 49: 59–63.

152. ImaniR, KarimiA, RouzbahaniR, RouzbahaniA (2008) Seroprevalence of HBV, HCV and HIV infection among intravenous drug users in Shahr-e-Kord, Islamic Republic of Iran. East Mediterr Health J 14: 1136–1141.

153. ShamaeiM, MarjaniM, BaghaeiP, ChitsazE, Rezaei TabarE, et al. (2009) Drug abuse profile - patient delay, diagnosis delay and drug resistance pattern - among addict patients with tuberculosis. Int J STD AIDS 20: 320–323.

154. PourahmadM, JavadyA, KarimiI, AtaeiB, KassaeianN (2007) Seroprevalence of and risk factors associated with hepatitis B, hepatitis C, and human immunodeficiency virus among prisoners in Iran. Infect Dis Clin Prac 15: 368–372.

155. ZamaniS, KiharaM, GouyaMM, VazirianM, Ono-KiharaM, et al. (2005) Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS 19: 709–716.

156. Farhoudi B, Montevalian A, Motamedi M, Khameneh MM, Mohraz M, et al.. (2003) Human immunodeficiency virus and HIV - associated tuberculosis infection and their risk factors in injecting drug users in prison in Iran. Tehran: Iran Ministry of Health.

157. KhodadadizadehA, Esmaeili NadimiA, HossieniSH, Shabani SharbabakiZ (2006) The prevalence of HIV, HBV and HCV in narcotic addicted persons referred to the out patient clinic of rafsanjan university of medical sciences in 2003 [Persian]. J Rafsanjan Univ Med Sci 5: 21–30.

158. AlaviSM, BehdadF (2010) Seroprevalence study of hepatitis C and hepatitis B virus among hospitalized intravenous drug users in Ahvaz, Iran (2002–2006). Hepat Mon 10: 101–104.

159. DavoodianP, DadvandH, MahooriK, AmoozandehA, SalavatiA (2009) Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis 13: 356–358.

160. BehnazK, AbdollahA, FatemeF, MohammadrezaR (2007) Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Gorgan prisoners. Journal of Medical Sciences 7: 252–254.

161. AlizadehAH, AlavianSM, JafariK, YazdiN (2005) Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan–Iran. World J Gastroenterol 11: 4085–4089.

162. Mir-NasseriMM, MohammadkhaniA, TavakkoliH, AnsariE, PoustchiH (2011) Incarceration is a major risk factor for blood-borne infection among intravenous drug users. Hepat Mon 11: 19–22.

163. SharifM, SherifA, SayyahM (2009) Frequency of HBV, HCV and HIV infections among hospitalized injecting drug users in Kashan. Indian J Sex Transm Dis 30: 28–30.

164. AlaviSM, AlaviL (2009) Seroprevalence study of HCV among hospitalized intravenous drug users in Ahvaz, Iran (2001–2006). J Infect Public Health 2: 47–51.

165. AlaviSM, EtemadiA (2007) HIV/HBV, HIV/HCV and HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pakistan Journal of Medical Sciences 23: 510–513.

166. RahbarAR, RooholaminiS, KhoshnoodK (2004) Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. International Journal of Drug Policy 15: 151–155.

167. Sharifi-MoodB, MetanatM (2006) Infection among hospitalized injection drug users. Journal of Medical Sciences 6: 686–689.

168. Mirahmadizadeh A, Kadivar M, Hemmati A, Javadi A (2004) Infection with HIV and hepatitis C and B viruses among injecting drug users in Shiraz, Southern Iran [Abstract WePeC5981]. In: Proceedings AIDS 2004 - XV International AIDS Conference; 11–16 July 2004; Bangkok, Thailand.

169. Nowroozi A, Zali M, Gooya M, Kowsarian P, Raoufi M (1998) The simultanity of HIV, and HBV, HCV and syphilis among the addicted prisoners [Abstract 60835]. AIDS 1998 - XII International AIDS Conference; 28 June–3 July 1998; Geneva, Switzerland.

170. AlavianSM, MirahmadizadehA, JavanbakhtM, KeshtkaranA, HeidariA, et al. (2013) Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon 13: 9.

171. AzarkarZ, SharifzadehG (2010) Evaluation of the prevalence of Hepatitis B, Hepatitis C, and HIV in inmates with drug-related convictions in Birjand, Iran in 2008. Hepat Mon 10: 26–30.

172. MirahmadizadehAR, MajdzadehR, MohammadK, MHF (2009) Prevalence of HIV and hepatitis C virus infections and related behavioral determinants among injecting drug users of drop-in centers in Iran. Iranian Red Crescent Medical Journal 11: 325–329.

173. AminiS, MahmoodabadiSA, LamianS, JoulaieM, FarahaniMM (2005) Prevalence of hepatitis G virus (HGV) in high-risk groups and blood donors in Tehran, Iran. Iranian Journal of Public Health 34: 41–46.

174. Alaei K, Alaei A, Mansoori D, Tabar, Heravi, et al.. (2002) The epidemiological status of IDU and HIV infection in addict cases submitted to HIV/STI/IDU Counseling and Care Center in Kermanshah province [Abstract LbPp2211]. In: Proceedings: AIDS 2002 - XIV International AIDS Conference; 7–12 July 2002; Barcelona, Spain.

175. RamiaS, KlaymeS, NamanR (2003) Infection with hepatitis B and C viruses and human retroviruses (HTLV-I and HIV) among high-risk Lebanese patients. Ann Trop Med Parasitol 97: 187–192.

176. ElhartiE (2002) HIV epidemiology in Morocco: a nine-year survey (1991–1999). ElHarti E, personal communication, updated data up to 2008. International journal of STD and AIDS 13: 839–842.

177. StulhoferA, ChettyA, RabieRA, JwehanI, RamlawiA (2012) The prevalence of HIV, HBV, HCV, and HIV-related risk-taking behaviors among Palestinian injecting drug users in the East Jerusalem Governorate. J Urban Health 89: 671–676.

178. PlattL, VickermanP, CollumbienM, HasanS, LaljiN, et al. (2009) Prevalence of HIV, HCV and sexually transmitted infections among injecting drug users in Rawalpindi and Abbottabad, Pakistan: evidence for an emerging injection-related HIV epidemic. Sex Transm Infect 85(Suppl 2): ii17–22.

179. Rahman K, Akhtar A, Aslam M (2006) Seroprevalence of HIV, HBV & HCV in drug users in Pakistan [Abstract CDC0097]. In: Proceedings AIDS 2006 - XVI International AIDS Conference; 13–18 August 2006; Toronto, Canada.

180. Nai Zindagi, Punjab Provincial AIDS Control Program (2005) The lethal overdose: injecting drug use and HIV/AIDS. Lahore: Government of Punjab.

181. AchakzaiM, KassiM, KasiPM (2007) Seroprevalences and co-infections of HIV, hepatitis C virus and hepatitis B virus in injecting drug users in Quetta, Pakistan. Trop Doct 37: 43–45.

182. Bokhari A, Emmanuel F, Abbas S (2006) Integrated biological & behavioral surveillance: results of pilot studies in Pakistan [Abstract MOPE0552]. In: Proceedings AIDS 2006 - XVI International AIDS Conference; 13–18 August 2006; Toronto, Canada.

183. Abbasi B, Somroo F (2005) HIV outbreak among injecting drug users in larkana, pakistan a serious threat for generalized epidemic [Abstract WeOa0305} IAS 2005 - The 3rd IAS Conference on HIV Pathogenesis and Treatment; 24–27 July 2005; Rio de Janeiro, Brazil.

184. AbbasiS, FaqirF, KhanS, ZaidiSK, AhmedSQ, et al. (2009) A serological study of hepatitis C and human immunodeficiency virus in a cohort of intravenous drug users in Quetta, Balochistan. Journal of Postgraduate Medical Institute 23: 3–6.

185. ShahSA, AltafA, MujeebSA, MemonA (2004) An outbreak of HIV infection among injection drug users in a small town in Pakistan: potential for national implications. Int J STD AIDS 15: 209.

186. Akhtar A, Aslam M, Zafar M (2004) Determinants of HIV risky behaviors among drug users in Faisalabad Pakistan [Abstract C11530]. In: Proceedings AIDS 2004 - XV International AIDS Conference; 11–16 July 2004; Bangkok, Thailand.

187. IqbalJ, RehanN (1996) Sero-prevalence of HIV: six years' experience at Shaikh Zayed Hospital, Lahore. J Pak Med Assoc 46: 255–258.

188. KhananiMR, AnsariAS, KhanS, SomaniM, KazmiSU, et al. (2010) Concentrated epidemics of HIV, HCV, and HBV among Afghan refugees. J Infection 61: 434–437.

189. UrRehman N (2002) Injecting drug use and HIV/AIDS in pakistan [Abstract MoPeD3667]. In: Proceedings AIDS 2002 - XIV International AIDS Conference; 7–12 July 2002; Barcelona, Spain.

190. World Health Organization Database of notified HIV/AIDS cases. Cairo: Eastern Mediterranean Region Office of the World Health Organization.

191. Mohtasham AmiriZ, RezvaniM, Jafari ShakibR, Jafari ShakibA (2007) Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province. East Mediterr Health J 13: 250–256.

192. KheirandishP, SeyedAlinaghiS, JahaniM, ShirzadH, Seyed AhmadianM, et al. (2009) Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health 86: 902–908.

193. KeramatF, EiniP, MajzoobiMM (2011) Seroprevalence of HIV, HBV and HCV in persons referred to hamadan behavioral counseling center, west of Iran. Iranian Red Crescent Medical Journal 13: 42–46.

194. VahdaniP, Hosseini-MoghaddamSM, FamilyA, Moheb-DezfouliR (2009) Prevalence of HBV, HCV, HIV and syphilis among homeless subjects older than fifteen years in Tehran. Arch Iran Med 12: 483–487.

195. ZamaniS, IchikawaS, NassirimaneshB, VazirianM, IchikawaK, et al. (2007) Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 18: 359–363.

196. NokhodianZ, AtaeiB, KassaianN, YaranM, HassannejadR, et al. (2012) Seroprevalence and risk factors of hepatitis C virus among juveniles in correctional center in Isfahan, Iran. International Journal of Preventive Medicine 3: S113–117.

197. SayadB, SaeedFS, KeyvaniH, RezaliM, AsadiT, et al. (2008) Seroepidemiology of hepatitis C in Kermanshah (West of Iran, 2006). Hepat Mon 8: 141–146.

198. NokhodianZ, MeshkatiM, AdibiP, AtaeiB, KassaianN, et al. (2012) Hepatitis C among intravenous drug users in Isfahan, Iran: A study of seroprevalence and risk factors. International Journal of Preventive Medicine 3: S131–138.

199. ZaliMR, AghazadehR, NowrooziA, Amir-RasoulyH (2001) Anti-HCV antibody among Iranian IV drug users: is it a serious problem. Arch Iranian Med 4: 115–119.

200. AtaeiB, BabakA, YaranM, KassaianN, NokhodianZ, et al. (2011) Hepatitis C in intravenous drug users: Seroprevalence and risk factors [Persian]. Journal of Isfahan Medical School 28: 1–9.

201. SarkariB, EilamiO, KhosravaniA, AkbartabartoriM, TabatabaeeM (2011) High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, Southwest of Iran. International Journal of Infectious Diseases 15: S82.

202. KaffashianA, NokhodianZ, KassaianN, BabakA, YaranM, et al. (2011) The experience of hepatitis C screening among prison inmates with drug injection history [Persian]. Journal of Isfahan Medical School 28.

203. KassaianN, AdibiP, KafashaianA, YaranM, NokhodianZ, et al. (2012) Hepatitis C virus and associated risk factors among prison inmates with history of drug injection in Isfahan, Iran. International Journal of Preventive Medicine 3.

204. NobariRF, MeshkatiM, AtaeiB, YazdaniMR, HeidariK, et al. (2012) Identification of patients with hepatitis c virus infection in persons with background of intravenous drug use: the first community announcementbased study from Iran. International Journal of Preventive Medicine 3.

205. RehanN, BokhariA, NizamaniNM, JacksonD, NaqviHR, et al. (2009) National study of reproductive tract infections among high risk groups of Lahore and Karachi. J Coll Physicians Surg Pak 19: 228–231.

206. AhmedF, IrvingWL, AnwarM, MylesP, NealKR (2011) Prevalence and risk factors for hepatitis C virus infection in Kech District, Balochistan, Pakistan: most infections remain unexplained. A cross-sectional study. Epidemiol Infect 1–8.

207. ButtA, JafriW, JanjuaN, PashaO (2010) Seroprevalence and risk factors for hepatitis C infection among male prisoners in Karachi, Pakistan. Am J Gastroenterol 105: S112.

208. Ur RehmanL, UllahI, AliI, KhanIA, IqbalA, et al. (2011) Active hepatitis C infection and HCV genotypes prevalent among the IDUs of Khyber Pakhtunkhwa. Virology Journal 8.

209. AliI, SiddiqueL, RehmanLU, KhanNU, IqbalA, et al. (2011) Prevalence of HCV among the high risk groups in Khyber Pakhtunkhwa. Virol J 8: 296.

210. NjohJ, ZimmoS (1997) Prevalence of antibodies to hepatitis C virus in drug-dependent patients in Jeddah, Saudi Arabia. East Afr Med J 74: 89–91.

211. IqbalN (2000) Substance dependence. A hospital based survey. Saudi Med J 21: 51–57.

212. AlzahraniAJ, Dela CruzDM, ObeidOE, BukhariHA, Al-QahtaniAA, et al. (2009) Molecular detection of hepatitis B, hepatitis C, and torque teno viruses in drug users in Saudi Arabia. J Med Virol 81: 1343–1347.

213. OthmanBM, MonemFS (2002) Prevalence of hepatitis C virus antibodies among intravenous drug abusers and prostitutes in Damascus, Syria. Saudi Med J 23: 393–395.